This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Administration of flavopiridol with SAHA will result in extensive induction of apoptosis of cancer cells with enhanced therapeutic effects (1) Identify recommended phase II doses for the combination of flavopiridol and vorinostat in the treatment of acute leukemia; (2) Determine the safety, toxicities, tolerability, and maximum tolerated dose of the combination; (3) Observe clinical anti-leukemic effects of the combination; (4) Observe pharmacodynamic effects of the combination; (5) Observe the pharmacokinetics of each agent when administered in combination; (5) Observe leukemia gene expression patterns and correlate with response to treatment.
Showing the most recent 10 out of 367 publications